PPLPHARMA - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 2.7
| Stock Code | PPLPHARMA | Market Cap | 20,186 Cr. | Current Price | 152 ₹ | High / Low | 241 ₹ |
| Stock P/E | 27.4 | Book Value | 58.2 ₹ | Dividend Yield | 0.09 % | ROCE | 12.4 % |
| ROE | 9.74 % | Face Value | 10.0 ₹ | DMA 50 | 171 ₹ | DMA 200 | 190 ₹ |
| Chg in FII Hold | -0.61 % | Chg in DII Hold | 0.79 % | PAT Qtr | 151 Cr. | PAT Prev Qtr | 196 Cr. |
| RSI | 29.1 | MACD | -6.33 | Volume | 23,55,288 | Avg Vol 1Wk | 65,71,847 |
| Low price | 148 ₹ | High price | 241 ₹ | PEG Ratio | 1.23 | Debt to equity | 0.12 |
| 52w Index | 3.70 % | Qtr Profit Var | 27.4 % | EPS | 5.39 ₹ | Industry PE | 29.0 |
📊 Chart & Trend Analysis: PPLPHARMA is trading at ₹152, well below its 50 DMA (₹171) and 200 DMA (₹190), reflecting a bearish structure. RSI at 29.1 indicates oversold conditions, while MACD (-6.33) confirms negative momentum. Bollinger Bands show price hugging the lower band, suggesting persistent selling pressure. Current volume (23,55,288) is significantly lower than the 1-week average (65,71,847), indicating weak participation.
📈 Momentum Signals: Short-term momentum remains weak, with RSI in oversold territory and MACD negative. A reversal signal may emerge if RSI climbs above 35 and price sustains above ₹160.
💡 Entry Zone: ₹148–₹155 (support near 52-week low)
🚪 Exit Zone: ₹170–₹185 (resistance near 50 DMA & 200 DMA)
🔎 Trend Status: The stock is reversing downward with strong bearish bias, showing limited reversal potential unless RSI and volume recover.
Positive
- EPS at ₹5.39 reflects earnings capacity.
- Debt-to-equity ratio at 0.12 shows low leverage.
- PEG ratio at 1.23 suggests fair growth-adjusted valuation.
- Increase in DII holding (+0.79%) signals domestic institutional support.
Limitation
- Price trading below both 50 DMA and 200 DMA indicates weak technical strength.
- ROCE (12.4%) and ROE (9.74%) remain moderate compared to peers.
- Dividend yield at 0.09% is negligible.
- Volume collapse compared to weekly average signals lack of investor interest.
Company Negative News
- Decline in FII holding (-0.61%) signals reduced foreign investor confidence.
- Quarterly PAT declined to ₹151 Cr. vs ₹196 Cr., showing earnings pressure.
Company Positive News
- Increase in DII holding reflects domestic institutional optimism.
- Quarterly profit variation at 27.4% highlights operational resilience despite decline.
Industry
- Industry PE at 29.0 is slightly higher than PPLPHARMA’s 27.4, suggesting fair valuation relative to peers.
- Pharmaceutical sector demand remains structurally strong, supported by healthcare needs and innovation.
Conclusion
⚖️ PPLPHARMA is reversing downward with strong bearish bias, trading well below key moving averages and showing weak momentum. While fundamentals show low leverage and fair PEG ratio, declining profits, weak efficiency metrics, and poor technical signals limit upside. Traders may consider entry near ₹148–₹155 with exit targets around ₹170–₹185. Sustained reversal requires RSI recovery above 35, stronger volume, and price stability above 50 DMA.